The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1521
Oxymetazoline Cream (Rhofade) for Rosacea
The full article is available to subscribers Subscriber Login   

The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha2-adrenergic receptor agonist, was approved in 2013 as a 0.33% gel (Mirvaso) for the same indication.1 Like Mirvaso, Rhofade is not indicated for treatment of inflammatory lesions of rosacea. Oxymetazoline has been available over the counter for many years as a nasal decongestant spray (Afrin, and others).

TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial condition of unknown cause characterized by erythema, telangiectasia, and/or acneiform lesions (papules and pustules), usually on the central part of the face. Avoidance of exposure to extremes of temperature, hot baths ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Oxymetazoline Cream (Rhofade) for Rosacea
Article code: 1521c
 Electronic, downloadable article - $25